The University Of Birmingham — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

8 Recruiting

4 Completed trials

17 Countries active

45 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 6 Phase II/III: 3 Phase II: 3 Phase I/II: 2

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute myeloid leukaemia 2 Rhabdomyosarcoma 2 Ewing's sarcoma 2 Germ cell cancer 1 Neuroblastoma 1 Ewing´s sarcoma metastatic 1 Extra-osseous Ewing´s sarcoma metastatic 1 Medulloblastoma 1 Ewing's sarcoma recurrent 1 Hepatocellular carcinoma 1 Extra-osseous Ewing's sarcoma recurrent 1 Hepatoblastoma 1

Top IMPs

CAPECITABINE 1 DINUTUXIMAB BETA 1 GEMTUZUMAB OZOGAMICIN 1 HYDROXYCARBAMIDE 1 INDOCYANINE GREEN 1 LENVATINIB 1 LOMUSTINE 1 LONCASTUXIMAB TESIRINE 1 ODRONEXTAMAB 1 PEGINTERFERON ALFA-2A 1 REGORAFENIB 1 RUXOLITINIB 1

All trials

14 total

Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery Pending

2024-514089-37-00 Phase II 1 country INDOCYANINE GREEN
BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending

2024-516115-24-00 Phase I/II 10 countries DINUTUXIMAB BETA; TEMOZOLOMIDE
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Recruiting

2024-510575-38-00 Phase II/III 6 countries LONCASTUXIMAB TESIRINE; ODRONEXTAMAB
INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting

2024-511989-36-00 Phase III 5 countries
VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study Recruiting

2024-516116-19-00 Phase II 1 country VENETOCLAX
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Phase III 1 country HYDROXYCARBAMIDE; PEGINTERFERON ALFA-2A; RUXOLITINIB
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting

2024-510578-25-00 Phase III 10 countries LOMUSTINE
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Phase I/II 16 countries REGORAFENIB
Paediatric Hepatic International Tumour Trial Recruiting

2024-516110-38-00 Phase III 10 countries
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting

2024-516078-31-00 Phase II/III 10 countries LENVATINIB
CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk orophar… Ended

2024-516108-41-00 Phase III 1 country
Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin… Ended

2024-516112-21-00 Phase III 2 countries GEMTUZUMAB OZOGAMICIN
STAR-TREC: Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision fo… Ended

2024-516106-31-00 Phase II/III 3 countries CAPECITABINE
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended

2024-518931-12-00 Phase II 5 countries

Showing 1–14 of 14 trials

← All sponsors A–Z